Elicera Therapeutics develops new cancer treatment with help of advanced cell lab in Flemingsberg

Uppsala-based Elicera Therapeutics is using the Pre-GMP core facility at Vecura in Flemingsberg as a first step in a study aimed at creating a new treatment for lymph node cancer.

The pre-GMP lab at Campus Flemingsberg makes it possible to use a new method to automate the process of genetically modifying cells for research studies.
“The facility allows us to benefit from a completely closed and automated system that reduces the workload for staff and further ensures quality,” says Magnus Essand, Research Director at Elicera.
In the Pre-GMP lab, the process can be developed and fine-tuned while staff at Vecura receive training in the new methods.

Activating the immune system
The establishment of Elicera Therapeutics was based on research conducted at Uppsala University with the aim of using modified cells – CAR-T cells – to develop new cancer treatments. Cells taken from patients develop the ability to activate the body’s own immune system in the fight against cancer.

The goal of the current study is to identify a treatment for patients with Non-Hodgkin’s lymphoma, a form of lymph node cancer.
“There are currently two approved treatments for the disease, but they don’t work for all patients. We hope that our treatment can also be used by these patients and prevent recurrence,” says Essand, adding: “We hope to develop a curative treatment for these patients.”

Elicera Therapeutics recently received a grant from the European Innovation Council (EIC) to help them grow further. In the future, there are plans to use the company’s findings to develop treatments for patients with brain cancer.

Read more on the Elicera Therapeutics homepage at: elicera.com.

Stockholm region’s only GameTech hub is being built in Flemingsberg

In September this year, Press Start took the next step in developing the Stockholm region’s GameTech ecosystem. Since then, the community has continued to grow, more studios have joined, and work on the next major initiative has gained momentum. So, what has happened so far, and what comes next?

CSIB: New interdisciplinary center brings research together to tackle future infectious threats

Center for Systems Infection Biology (CSIB) was recently inaugurated at Campus Flemingsberg. The new interdisciplinary initiative brings together research, advanced infrastructure and expertise to deepen the understanding of infectious diseases and accelerate the path from research to clinical application. We met with Director Ujjwal Neogi and Co-director Iva Filipovic to talk about the center’s goals, its strong focus on collaboration, and its ambition to contribute to pandemic preparedness.

Vecura – 30 Years Dedicated to the Medicine of the Future

In Flemingsberg, pioneers have helped shape the medicine of the future since 1996. This year, the manufacturing unit Vecura celebrates 30 years of supporting the development of cell and gene therapies – advanced therapies that enable more personalized treatments. We spoke with Pontus Blomberg, strategic advisor and former Director of Operations, who has helped build one of Sweden’s leading laboratories in the field.

Vill du veta mer?
Prenumerera på vårt nyhetsbrev.

Vill du veta mer?
Prenumerera på vårt nyhetsbrev.

CF_logo_neg
2022-09-13T09:21:55+02:00
Go to Top